smartbax
Infectious Disease Therapeutics
$6.4Mtotal raised · 6 rounds on record
1open role
Seedlatest round · Jun 2026 · 4 mo ago
2backers · High-Tech Gründerfonds, Bayern Kapital
Overview
Smartbax is dedicated to developing innovative antibiotics to combat the rising threat of multi-drug-resistant bacteria and protect global health.
Funding and backers
Total raised
$6.4M
6 rounds on record
Latest round
Seed
Jun 2026 · 4 mo ago
Team
11-50
employees, estimated range
Hiring now
1
+1 posted in 30 days
Grants
$2.8M
3 grants · CORDIS
Backers
2
High-Tech Gründerfonds, Bayern Kapital
The money's age
Fresh money
4 months since the last round · and hiring
Momentum
33/100
hiring for its size, fresh money
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Jul 1
Won a grant $494k · CORDIS
Jun 30
Raised a round Seed · The Manila Times
Nov 1, 2025
Won a grant $1.8M · CORDIS
Oct 22, 2025
Raised a round Seed $5.1M · YahooFinance
May 23, 2023
Raised a round Seed $1.3M · businesswire
May 1, 2023
Won a grant $571k · CORDIS
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Grant | Jul 2026 | $494k | — | CORDIS |
| Seed | Jun 2026 | — | — | The Manila Times |
| Grant | Nov 2025 | $1.8M | — | CORDIS |
| Seed | Oct 2025 | $5.1M | — | YahooFinance |
| Seed | May 2023 | $1.3M | — | businesswire |
| Grant | May 2023 | $571k | — | CORDIS |
Registers and programsofficial lists and records that name the company
| Legal entity | smartbax GmbH | its site |
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Our Mission and Innovation We are a biotechnology pioneer dedicated to solving one of the greatest challenges in modern medicine: the…
Arrowsmith Inc. is a research-driven biotech focused on bringing next-generation phage therapy into clinical use for patients suffering…
Antibiotics once saved us—now it’s our turn. pRxcision® is the first AI-powered infectious disease platform delivering real-time decision…
OtoNexus Medical Technologies is developing an AI-assisted ultrasound otoscope intended to improve the identification and management of…
Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation adjuvanted subunit vaccines to the market…
Welcome to Resistell, where we harness cutting-edge nanomotion technology to provide the fastest, most accurate ultra-rapid antibiotic…
Jobs
≈ $136k – $250k per year (Estimated) · In office · Full-Time · 10+ years exp · Munich
Apply
Growth
Hiring Momentum
28/100
Slowing
Open positions
1
0 opened / 0 closed in 30 days
ATS activity
Every ~9 hours
11/09/2026
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Biotech
100% ▲
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
Bayern KapitalVia a fund
High-Tech GründerfondsVia a fund
517 portfolio companies
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely
News
smartbax secures additional financing to advance lead antibiotic program to IND filing
Munich, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the successful second closing of its Pre-Series A financing round. The additional
Read more
Report
Report
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
smartbax GmbH
Read more
Report
smartbax in-licenses lead antibacterial compound targeting Gram-negative infections from Aicuris
Munich, Germany, Jan. 20, 2026 (GLOBE NEWSWIRE) -- smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the in-licensing of a new compound class from the antibacterial portfolio of Aicur
Read more
Report
smartbax: €4.7 Million Pre-Series A Funding Raised To Advance Antibiotics Against Drug-Resistant Bacteria
smartbax, a biotechnology company pioneering innovative small-molecule antibiotics to combat multidrug-resistant bacteria, announced the first closing of its €4.7 million Pre-Series A financing round. The investment was led by new backers Anobis Asset and
Read more
Report
smartbax announces a €4.7 M Pre-Series A round to advance novel antibiotic compound through preclinical stage
Lead antibacterial compound against a novel target in Gram-negative bacteria validated in infection modelsProgressing a platform of small-molecule enzymatic activators that induce self-digestion of bacteria as novel mode of action against multi-drug resis
Read more
Report
smartbax Announces Seed Financing of €1.2 Million to Develop Next-generation Antibiotics
smartbax, a biotech company developing next-generation antibiotics against multi-drug resistant bacteria, today announced the close of its seed financing rou...
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
1
Countries
1
Busiest office
Munich
Munich
Germany
HQ
1 open roles 1 posted in 90 days 10-50 est. staff
hires for Biotech